MedTrace Logo

Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma

NCT07782632 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 467

Last updated 2026-08-24

No results posted yet for this study

Summary

This multicenter retrospective cohort study aims to evaluate the prognostic value of functional liver volume and total liver volume in patients with unresectable hepatocellular carcinoma (HCC) undergoing immunotherapy. The study explores whether baseline liver volume metrics can effectively predict survival outcomes and treatment responses in this patient population to assist in clinical decision-making.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

OTHER

Baseline Liver Volume Volumetric Analysis

An observational evaluation based on the quantification of baseline pre-treatment functional liver volume (FLV) and total liver volume (TLV) derived from imaging datasets. These liver volume metrics are analyzed in correlation with clinical data to assess their prognostic potential for treatment response and overall survival in patients with unresectable hepatocellular carcinoma (HCC) receiving immunotherapy. No experimental treatment allocation or clinical intervention is performed.

Sponsors & Collaborators

  • Anhui Provincial Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2026-12-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07782632 on ClinicalTrials.gov